Home > Insider Trading > Filing (0000899243-19-021334)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1427570	Obalon Therapeutics Inc	OBLN	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1207833	L Arnold Oronsky	2710 Sand Hill Road, Suite 200 Menlo Park CA 94025	No	No	Yes	No
1276600	Khaled Nasr	2710 Sand Hill Road, Suite 200 Menlo Park CA 94025	No	No	Yes	No
1293171	H Gilbert Kliman	2710 Sand Hill Road, Suite 200 Menlo Park CA 94025	No	No	Yes	No
1443898	Interwest Partners X Lp	2710 Sand Hill Road, Suite 200 Menlo Park CA 94025	No	No	Yes	No
1460207	Interwest Management Partners X, Llc	2710 Sand Hill Road, Suite 200 Menlo Park CA 94025	No	No	Yes	No
1553019	Keval Desai	2710 Sand Hill Road, Suite 200 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-08-06	25,000	$4.00	380,224	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common	Warrants (Right to buy)	Acquisiton	2019-08-06	18,750	$0.00	18,750	$4.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,750	2019-08-06	2024-08-05	No	4	P	Direct

Footnotes

The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants.
These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.